Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Sisunatovir in Healthy Chinese Participants
NCT05987072Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sisunatovir in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at Day 8, Area Under the Plasma Concentration-time Profile from Time Zero to Time 12 Hours and 2 more. Started Nov 2023; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05987072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987072.